Advancing next-generation RNA therapeutics beyond the liver through breakthrough delivery technologies

通过突破性递送技术，推动下一代RNA疗法超越肝脏应用

SUZHOU, China and BOSTON

中国苏州和波士顿

,

，

April 10, 2026

2026年4月10日

/PRNewswire/ -- Vivatides Therapeutics, a global biotechnology company focused on developing extrahepatic RNA-targeting therapeutics, announced the successful closing of an oversubscribed $54 million Series A financing. The round was co-led by Qiming Venture Partners and a leading industry fund, with participation from Highlight Capital, a leading venture fund, and TF Capital.

/PRNewswire/ -- 全球生物技术公司Vivatides Therapeutics专注于开发肝外RNA靶向治疗药物，宣布成功完成超额认购的5400万美元A轮融资。本轮融资由启明创投和一家行业领先基金共同领投，亮点资本和TF Capital等领先风险投资基金参与跟投。

Existing investor Apricot Capital also continued to support the company with additional investment. Proceeds from the financing will be used to further advance Vivatides' extrahepatic delivery platform, accelerate multiple pipeline programs into clinical development, and expand its global team and R&D network.

现有投资者Apricot Capital也继续通过追加投资来支持该公司。融资所得将用于进一步推进Vivatides的肝外递送平台，加速多个管线项目进入临床开发，并扩大其全球团队和研发网络。

As an emerging player in the RNA therapeutics field, Vivatides has completed both its seed and Series A financings within less than one year of founding, underscoring strong investor confidence in the company's technological innovation and execution capabilities in extrahepatic RNA delivery..

作为RNA治疗领域的一名新兴参与者，Vivatides在成立不到一年的时间内就完成了种子轮和A轮融资，表明投资者对该公司在肝外RNA递送方面的技术创新和执行能力充满信心。

RNA therapeutics, with their broad target space, high specificity, and durable efficacy, are poised to become the third major therapeutic modality following small molecules and antibodies. However, traditional RNA therapeutics have largely been limited to liver-targeted applications due to delivery challenges.

RNA 疗法因其广泛的作用靶点、高特异性和持久的疗效，有望成为继小分子和抗体之后的第三大治疗方式。然而，由于递送方面的挑战，传统的 RNA 疗法在很大程度上仅限于针对肝脏的应用。

Diseases involving extrahepatic tissues remain significantly underserved and represent the next major frontier for .

涉及肝外组织的疾病仍然服务不足，代表了下一个主要领域。

innovation.

创新。

With

随着

advances in extrahepatic delivery technologies, RNA therapeutics are rapidly expanding beyond rare diseases into large, chronic disease areas such as hyperlipidemia, hypertension, and oncology, unlocking substantial market potential.

肝外递送技术的进步使RNA疗法正在迅速超越罕见病领域，扩展到高脂血症、高血压和肿瘤学等大型慢性疾病领域，释放出巨大的市场潜力。

Founded in 2025, Vivatides has been dedicated to the innovation and translation of proprietary extrahepatic RNA delivery technologies. The company's globally experienced leadership team includes experts from leading RNA therapeutics companies. The team has previously led or played key roles in multiple extrahepatic RNA programs, several of which have progressed into clinical development.

Vivatides 成立于2025年，一直致力于创新和转化其专有的肝外RNA递送技术。公司由具有全球经验的领导团队组成，成员包括来自领先的RNA治疗公司的专家。该团队此前曾领导或在多个肝外RNA项目中发挥关键作用，其中几个项目已进入临床开发阶段。

Leveraging this deep expertise, Vivatides has built a differentiated extrahepatic delivery platform with capabilities spanning both siRNA and antisense oligonucleotides (ASO). The company has achieved key advances in ligand conjugation, delivery efficiency, tissue targeting specificity, and safety, with encouraging in vivo results already demonstrated.

利用这一深厚的专业知识，Vivatides打造了一个差异化的肝外递送平台，其能力涵盖siRNA和反义寡核苷酸（ASO）。该公司在配体结合、递送效率、组织靶向特异性和安全性方面取得了关键进展，并已展示了令人鼓舞的体内实验结果。

Combined with strong capabilities in sequence design and target discovery, the platform enables rapid parallel advancement and expansion of a diversified pipeline..

结合强大的序列设计和靶点发现能力，该平台能够快速并行推进和扩展多样化的管线。

'Extrahepatic delivery is the key that will unlock RNA therapeutics from niche rare diseases to broad chronic indications,' said Keming Zhou, Founder of Vivatides Therapeutics. 'We are honored to have the support and recognition of leading investors. This financing will accelerate the evolution of our platform and pipeline, advancing innovative RNA therapeutics into extrahepatic disease areas.

“肝外递送是将RNA治疗从罕见病的小众领域扩展到广泛慢性病的关键，”Vivatides Therapeutics创始人周克明表示。“我们深感荣幸能够获得领先投资者的支持与认可。这笔融资将加速我们平台和管线的发展，推动创新的RNA治疗进入肝外疾病领域。”

We believe that overcoming delivery barriers will enable RNA therapeutics to transform treatment paradigms across a wide range of diseases. We also look forward to engaging with more long-term, value-driven partners to bring transformative therapies to patients worldwide.'.

我们相信，克服递送障碍将使RNA疗法能够转变广泛疾病的治疗模式。我们也期待与更多长期、价值驱动的合作伙伴合作，为全球患者带来变革性疗法。

Dr. Kan Chen, Partner at Qiming Venture Partners and Co-leads Qiming's investments in the healthcare sector

启明创投合伙人、共同领导启明医疗领域投资的陈侃博士

, commented: ' We have long been optimistic about the application potential of small nucleic acid drugs across a broader range of disease areas. Continuous advances in extrahepatic targeting technologies are steadily expanding their clinical frontiers. Vivatides Therapeutics has demonstrated solid technological expertise and efficient execution capabilities in this field, with encouraging progress achieved on its platform.

，评论道：“我们长期以来一直看好小核酸药物在更广泛疾病领域的应用潜力。随着肝外靶向递送技术的不断进步，其临床应用边界正在稳步拓展。维泰瑞隆在这一领域展现了扎实的技术实力和高效的执行能力，其平台建设也取得了令人鼓舞的进展。

We look forward to the company driving further technological breakthroughs, accelerating the clinical translation of its pipeline, and delivering safer and more effective innovative therapies to patients worldwide.'.

我们期待该公司推动进一步的技术突破，加速其管道的临床转化，并为全球患者提供更安全、更有效的创新疗法。

Dr. Wei Ding, Partner at Apricot Capital

丁伟博士，杏资本合伙人

, commented: 'As an early investor in Vivatides' seed round, we are delighted to see the company successfully complete its Series A financing and welcome new investors. Since its founding, Dr. Zhou and his team have consistently exceeded expectations with exceptional execution in platform development and pipeline advancement.

，评论道：“作为Vivatides种子轮的早期投资者，我们很高兴看到公司成功完成A轮融资并迎来新投资者。自成立以来，周博士及其团队在平台开发和产品线推进方面始终以卓越的执行力超越预期。

We look forward to Vivatides translating its differentiated platform into breakthrough therapies that benefit patients worldwide and leading the next wave of extrahepatic RNA therapeutics.'.

我们期待Vivatides将其差异化平台转化为惠及全球患者的突破性疗法，并引领肝外RNA治疗的下一波浪潮。

Following the financing, Vivatides will further accelerate preclinical optimization and IND-enabling studies, expand its R&D and management teams, and continue to strengthen its extrahepatic delivery platform. Looking ahead, the company will remain focused on addressing unmet medical needs in high-prevalence extrahepatic diseases, becoming a leader in RNA therapeutics and delivering more effective and safer treatment options to patients worldwide..

融资完成后，Vivatides 将进一步加速临床前优化和 IND 支持性研究，扩大其研发和管理团队，并继续加强其肝外递送平台。展望未来，该公司将继续专注于满足高发肝外疾病中未被满足的医疗需求，成为 RNA 治疗领域的领导者，为全球患者提供更有效、更安全的治疗选择。

SOURCE Vivatides Therapeutics

来源：Vivatides治疗公司

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示